W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...

NHS England's collaboration with BioNTech is crucial in discovering individuals who may benefit from the trial.

Cancer rates in 2025 are predicted to exceed the previous year's statistics, with one-in-three men and women both at risk of ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

After the success of the Phase Ib study, Assembly Bio’s herpes therapy will advance to Phase II trials in mid-2026.

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

Discover key insights from Roivant Sciences' Q1 2025 earnings call, including brepocitinib DM data milestones, financial strength, and strategic ...

The debate over artificial intelligence in Africa is sharply divided. One side argues the continent must invest heavily in AI ...